NasdaqGM:EYPTPharmaceuticals
EyePoint (EYPT) Q1 Loss Near US$85 Million Tests Bullish DURAVYU Narratives
EyePoint Pharmaceuticals (EYPT) opened 2026 with Q1 revenue of US$0.7 million, a basic EPS loss of US$0.99 per share and a net income loss of US$84.8 million, setting a clear tone for how profitability is tracking into the new year. The company has seen quarterly revenue move from US$24.5 million in Q1 2025 to US$0.7 million in Q1 2026, while quarterly basic EPS shifted from a loss of US$0.65 to a loss of US$0.99. The latest print keeps the focus squarely on how much cash the business is...